SEMAGLUTIDE
Semaglutide has also been extensively investigated in human clinical trials examining appetite regulation, satiety, energy intake, body weight, glucose metabolism, and cardiovascular outcomes. Its interaction with GLP-1 receptors in areas involved in appetite signaling has been a particularly significant area of scientific investigation.
Large clinical research programs, including the STEP and SUSTAIN trials, have contributed substantially to researchers' understanding of GLP-1 receptor agonism and its relationship with metabolic health, obesity, and type 2 diabetes.
Semaglutide itself is an active ingredient in approved prescription medicines for specific medical indications. However, the research product offered here is not an approved medication and should not be represented or used as a substitute for an approved pharmaceutical product.
For laboratory research purposes only. Not for human consumption.
Wilding et al., 2021, New England Journal of Medicine, STEP 1: A large randomized trial studying once-weekly semaglutide in adults with overweight or obesity. This is a cornerstone reference for the body-weight portion of the description.
Blundell et al., 2017, Diabetes, Obesity and Metabolism: Particularly useful for our wording about appetite, satiety, food cravings, energy intake, and body weight. The randomized study found lower energy intake and reduced hunger and cravings with semaglutide versus placebo.
Friedrichsen et al., 2021: Investigated semaglutide 2.4 mg in adults with obesity, specifically examining appetite, satiety, food cravings, energy intake and gastric emptying.
Marso et al., 2016, New England Journal of Medicine, SUSTAIN-6: A randomized cardiovascular-outcomes trial involving 3,297 people with type 2 diabetes, making it a strong reference for the cardiovascular/metabolic research mentioned in our description.
